173 related articles for article (PubMed ID: 24349459)
21. Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Xiao YS; Tang ZY; Fan J; Zhou J; Wu ZQ; Sun QM; Xue Q; Zhao Y; Liu YK; Ye SL
J Cancer Res Clin Oncol; 2004 Sep; 130(9):546-50. PubMed ID: 15071737
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.
Lee D; Chung YH; Kim JA; Park WH; Jin YJ; Shim JH; Ryu SH; Jang MK; Yu E; Lee YJ
Cancer; 2013 Jun; 119(12):2239-46. PubMed ID: 23564564
[TBL] [Abstract][Full Text] [Related]
23. Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-λ1 or PEG-interferon-λ1.
Tian S; Hui X; Fan Z; Li Q; Zhang J; Yang X; Ma X; Huang B; Chen D; Chen H
FASEB J; 2014 Aug; 28(8):3528-39. PubMed ID: 24769671
[TBL] [Abstract][Full Text] [Related]
24. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis.
Wu J; Yin Z; Cao L; Xu X; Yan T; Liu C; Li D
Medicine (Baltimore); 2018 Jul; 97(28):e11295. PubMed ID: 29995763
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53.
Hagiwara S; Kudo M; Nakatani T; Sakaguchi Y; Nagashima M; Fukuta N; Kimura M; Hayakawa S; Munakata H
Br J Cancer; 2007 Dec; 97(11):1532-7. PubMed ID: 17971768
[TBL] [Abstract][Full Text] [Related]
27. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
28. Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.
Palesch D; Bosinger SE; Mavigner M; Billingsley JM; Mattingly C; Carnathan DG; Paiardini M; Chahroudi A; Vanderford TH; Silvestri G
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720521
[TBL] [Abstract][Full Text] [Related]
29. Pegylation of IFN-alpha and antiviral activity.
Boulestin A; Kamar N; Sandres-Sauné K; Alric L; Vinel JP; Rostaing L; Izopet J
J Interferon Cytokine Res; 2006 Dec; 26(12):849-53. PubMed ID: 17238827
[TBL] [Abstract][Full Text] [Related]
30. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
31. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection.
Han M; Li Y; Wu W; Zhang Y; Yan W; Luo X; Ning Q
Antiviral Res; 2017 Nov; 147():75-85. PubMed ID: 28988797
[TBL] [Abstract][Full Text] [Related]
32. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
Lee S; Kim IH; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Lee CS; Choi CS; Cho EY; Kim HC
Intervirology; 2010; 53(3):146-53. PubMed ID: 20068348
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
Kojiro S; Yano H; Ogasawara S; Momosaki S; Takemoto Y; Nishida N; Kojiro M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):129-37. PubMed ID: 16706824
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
36. The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo.
Zhang Y; Wu Y; Ye S; Wang T; Zhao R; Chen F; Abe K; Jin X
Virus Res; 2013 Jan; 171(1):65-70. PubMed ID: 23123214
[TBL] [Abstract][Full Text] [Related]
37. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
38. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
[TBL] [Abstract][Full Text] [Related]
39. Pegylated interferon-α2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells.
Rendón-Huerta EP; Torres-Martínez A; Charles-Niño C; Rivas-Estilla AM; Paez A; Fortoul TI; Montaño LF
Ann Hepatol; 2013; 12(4):616-25. PubMed ID: 23813140
[TBL] [Abstract][Full Text] [Related]
40. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
